G protein-coupled receptors disrupted in human genetic disease

Methods in Molecular Biology

Volumn 448, Issue , 2008, Pages 109-137

  Thompson, Miles D ^a   Percy, Maire E ^b   Burnham, W McIntyre ^a   Cole, David E C ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Follicle stimulating hormone; G protein coupled receptor; Gain of function; Gonadotropin releasing hormone (GnRHR); Loss of function; Luteinizing hormone; Melanocortin; Monogenic disease; Parathyroid hormone; Rhodopsin; Thyrotropin

Indexed keywords

G PROTEIN COUPLED RECEPTOR;

GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HUMAN; METABOLISM; PHARMACOGENETICS; PHENOTYPE; REVIEW; SIGNAL TRANSDUCTION;

GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, GENETIC; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 43549102015     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-59745-205-2_7     Document Type: Article

References (141)

1. Spiegel, A. M. (1998) Introduction to G-protein-coupled signal transduction and human disease, in G proteins, receptors, and disease (A. M. Speigel, ed.), Humana Press, Totowa, NJ, pp. 1-21.
2. Rana, B. K., Shiina, T., and Insel, P. A. (2001) Genetic variations and polymorphisms of G protein-coupled receptors: functional and therapeutic implications. Annu. Rev. Pharmacol. Toxicol. 41, 593-624.
3. Spiegel, A. M., and Weinstein, L. S. (2004) Inherited diseases involving G proteins and G protein-coupled receptors. Annu. Rev. Med. 55, 27-39.
4. Tan, C. M., Brady, A. E., Nickols, H. H., Wang, Q., and Limbird, L. E. (2004) Membrane trafficking of G protein-coupled receptors. Annu. Rev. Pharmacol. Tox. 44, 559-609.
5. Spiegel, A. M. (1996) Defects in G protein-coupled signal transduction in human disease. Annu. Rev. Physiol. 58, 143-170.
6. Milligan, G. (2002) Strategies to identify ligands for orphan G-protein-coupled receptors. Biochem. Soc. Trans. 30, 789-793.
7. Small, K. M., Mcgraw, D. W., and Liggett, S. B. (2003) Pharmacology and physiology of human adrenergic receptor polymorphisms. Annu. Rev. Pharmacol. Toxicol. 43, 381-411.
8. Milligan, G., Stevens, P. A., Ramsay, D., and Mclean, A. J. (2002) Ligand rescue of constitutively active mutant receptors. Neurosignals. 11, 29-33.
9. Seifert, R., and Wenzel-Seifert, K. (2002) Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn-Schmiedebergs Arch. Pharmacol. 366, 381-416.
10. Bird, A. C. (1992) Investigation of disease mechanisms in retinitis-pigmentosa. Ophthal. Paediatr. Genet. 13, 57-66.
11. Almaghtheh, M., Gregory, C., Inglehearn, C., Hardcastle, A., and Bhattacharya, S. (1993) Rhodopsin mutations in autosomal-dominant retinitis-pigmentosa. Hum. Mutat. 2, 249-255.
12. Rana, B. K., Shiina, T., and Insel, P. A. (2001) Genetic variations and polymorphisms of G protein-coupled receptors: functional and therapeutic implications. Annu. Rev. Pharmacol. Toxicol. 41, 593-624.
13. Rim, J., and Oprian, D. D. (1995) Constitutive activation of opsin - interaction of mutants with rhodopsin kinase and arrestin. Biochemistry. 34, 11938-11945.
14. Sullivan, J. M., Scott, K M., Falls, H. F., Richards, J. E., and Sieving, P. A. (1993) A novel rhodopsin mutation at the retinal binding-site (Lys-296-Met) in Adrp. Invest. Ophthalmol. Vis. Sci. 34, 1149.
15. Sullivan, L. J., Makris, G. S., Dickinson, P., et al. (1993) A new codon 15 rhodopsin gene mutation in autosomal-dominant retinitis-pigmentosa is associated with sectorial disease. Arch. Ophthalmol. 111, 1512-1517.
16. Bunge, S., Wedemann, H., David, D., et al. (1993) Molecular analysis and genetic-mapping of the rhodopsin gene in families with autosomal-dominant retinitis-pigmentosa. Genomics. 17, 230-233.
17. Farrar, G. J., Mcwilliam, P., Bradley, D. G., et al. (1990) Autosomal dominant retinitispigmentosa - linkage to rhodopsin and evidence for genetic-heterogeneity. Genomics. 8, 35-40.
18. Inglehearn, C. F., Lester, D. H., Bashir, R., et al. (1992) Recombination between rhodopsin and locus D3S47 (C17) in rhodopsin retinitis-pigmentosa families. Am. J. Hum. Genet. 50, 590-597.
19. Neidhardt, J., Barthelmes, D., Farahmand, F., Fleischhauer, J. C., and Berger, W. (2006) Different amino acid substitutions at the same position in rhodopsin lead to distinct phenotypes. Invest. Ophthalmol. Vis. Sci. 47, 1630-1635.
20. Andres, A., Kosoy, A., Garriga, P., and Manyosa, J. (2001) Mutations at position 125 in transmembrane helix III of rhodopsin affect the structure and signalling of the receptor. Eur. J. Biochem. 268, 5696-5704.
21. Andreoli, T. E. (1998) Diseases of receptors: Introductory comments. Am. J. Med. 105, 242-243.
22. Chen, C. K., Zhang, K., Church-Kopish, J., et al. (2001) Characterization of human GRK7 as a potential cone opsin kinase. Mol. Vis. 7, 305-313.
23. Dryja, T. P. (2000) Molecular genetics of Oguchi disease, fundus albipunctatus, and other forms of stationary night blindness: LVII Edward Jackson Memorial Lecture. Am. J. Ophthalmol. 130, 547-563.
24. Hayashi, T., Gekka, T., Takeuchi, T., Goto-Omoto, S., and Kitahara, K (2007) A novel homozygous GRK1 mutation (P391H) in 2 siblings with Oguchi disease with markedly reduced cone responses. Ophthalmology. 114, 134-141.
25. Duprez, L., Parma, J., Vansande, J., et al. (1994) Germline mutations in the thyrotropin receptor gene cause non-autoimmune autosomal-dominant hyperthyroidism. Nat. Genet. 7, 396-401.
26. Artuři, F., Capula, C., Chiefari, E., Filetti, S., and Russo, D. (1998) Thyroid hyperfunctioning adenomas with and without Gsp/TSH receptor mutations show similar clinical features. Exp. Clin. Endocrinol. Diabetes. 106, 234-236.
27. Kaczur, V., Takacs, M., Szalai, C., et al. (2000) Analysis of the genetic variability of the 1st (CCC/ACC, P52T) and the 10th exons (bp 1012-1704) of the TSH receptor gene in Graves' disease. Eur. J. Immunogenet. 27, 17-23.
28. Biebermann, H., Schoneberg, T., Hess, C., Germak, J., Gudermann, T., and Gruters, A. (2001) The first activating TSH receptor mutation in transmembrane domain 1 identified in a family with nonautoimmune hyperthyroidism. J. Clin. Endocrinol. Metab. 86, 4429-4433.
29. Jordan, N., Williams, N., Gregory, J. W., Evans, C., Owen, M., and Ludgate, M. (2003) The W546X mutation of the thyrotropin receptor gene: potential major contributor to thyroid dysfunction in a Caucasian population. J. Clin. Endocrinol. Metab. 88, 1002-1005.
30. Farid, N. R., and Szkudlinski, M. W. (2004) Minireview: structural and functional evolution of the thyrotropin receptor. Endocrinology. 145, 4048-4057.
31. Polak, M., Sura-Trueba, S., Chauty, A., Szinnai, G., Carre, A., and Castanet, M. (2004) Molecular mechanisms of thyroid dysgenesis. Horm. Res. 62, 14-21.
32. Gabriel, E. M., Bergert, E. R., Grant, C. S., van Heerden, J. A., Thompson, G. B., and Morris, J. C. (1999) Germline polymorphism of codon 727 of human thyroid-stimulating hormone receptor is associated with toxic multinodular goiter. J. Clin. Endocrinol. Metab. 84, 3328-3335.
33. Biebermann, H., Schoneberg, T., Krude, H., Gudermann, T., and Graters, A. (2000) Constitutively activating TSH-receptor mutations as a molecular cause of non-autoimmune hyperthyroidism in childhood. Arch. Surg. 385, 390-392.
34. Karges, B., Krause, G., Homoki, J., Debatin, K. M., de, R. N., and Karges, W. (2005) TSH receptor mutation V509A causes familial hyperthyroidism by release of interhelical constraints between transmembrane helices TMH3 and TMH5. J. Endocrinol. 186, 377-385.
35. Tonacchera, M., Agretti, P., Chiovato, L., et al. (2000) Activating thyrotropin receptor mutations are present in nonadenomatous hyperfunctioning nodules of toxic or autonomous multinodular goiter. J. Clin. Endocrinol. Metab. 85, 2270-2274.
36. Pohlenz, J., Pfarr, N., Krager, S., and Hesse, V. (2006) Subclinical hyperthyroidism due to a thyrotropin receptor (TSHR) gene mutation (S505R). Acta Paediatr. 95, 1685-1687.
37. Sadee, W., Hoeg, E., Lucas, J., and Wang, D. X. (2001) Genetic variations in human G protein-coupled receptors: Implications for drag therapy. AAPS Pharmsci. 3, E22. DOI: 10.1208/ps030322.
38. Kaczur, V., Puskas, L. G., Takacs, M., et al. (2003) Evolution of the thyrotropin receptor: a G protein coupled receptor with an intrinsic capacity to dimerize. Mol. Genet. Metab. 78, 275-290.
39. Bodenner, D. L., and Lash, R. W. (1998) Thyroid disease mediated by molecular defects in cell surface and nuclear receptors. Am. J. Med. 105, 524-538.
40. Yun, F. H., Wong, B. Y., Chase, M., et al. (2007) Genetic variation at the calcium-sensing receptor (CASR) locus: Implications for clinical molecular diagnostics. Clin. Biochem. Biochem. 40, 551-556
41. Pidasheva, S., D'Souza-Li, L., Canaff, L., Cole, D. E. C., and Hendy, G. N. (2004) CASRdb: Calcium-sensing receptor locus-specific database for mutations causing familial (benign) hypocalciuric hypercalcemia, neonatal severe hyperparathyroidism, and autosomal dominant hypocalcemia. Hum. Mutat. 24, 107-111.
42. Burren, C. P., Curley, A., Christie, P., Rodda, C. P., and Thakker, R. V. (2005) A family with autosomal dominant hypocalcaemia with hypercalciuria (ADHH): mutational analysis, phenotypic variability and treatment challenges. J. Pediatr. Endocrinol. Metab. 18, 9-99.
43. Hendy, G. N., Minutti, C., Canaff, L., et al. (2003) Recurrent familial hypocalcemia due to germline mosaicism for an activating mutation of the calcium-sensing receptor gene. J. Clin. Endocrinol. Metab. 88, 3674-3681.
44. Hendy, G. N., D'Souza-Li, L., Yang, B., Canaff, L., and Cole, D. E. C. (2000) Mutations of the calcium-sensing receptor (CASR) in familial hypocalciuric hypercalcemia, neonatal severe hyperparathyroidism, and autosomal dominant hypocalcemia. Hum. Mutat. 16, 281-296.
45. Gunn, I. R., and Gaffney, D. (2004) Clinical and laboratory features of calcium-sensing receptor disorders: a systematic review. Ann. Clin. Biochem. 41, 441-458.
46. Marx, S. J., and Simonds, W. F. (2005) Hereditary hormone excess: genes, molecular pathways, and syndromes. Endocr. Rev. 26, 615-661.
47. Chou, Y. H. W., Brown, E. M., Levi, T., et al. (1992) The gene responsible for familial hypocalciuric hypercalcemia maps to chromosome-3Q in four unrelated families. Nat. Genet. 1, 295-300.
48. Leech, C., Lohse, P., Stanojevic, V., Lechner, A., Goke, B., and Spitzweg, C. (2006) Identification of a novel inactivating R465Q mutation of the calcium-sensing receptor. Biochem. Biophys. Res. Commun. 342, 996-1002.
49. Janicic, N., Pausova, Z., Cole, D. E. C., and Hendy, G. N. (1995) Insertion of an Alu sequence in the Ca2+-sensing receptor gene in familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Am. J. Hum. Genet. 56, 880-886.
50. Cole, D. E. C., Janicic, N., Salisbury, S. R., and Hendy, G. N. (1997) Neonatal severe hyperparathyroidism, secondary hyperparathyroidism, and familial hypocalciuric hypercalcemia: multiple different phenotypes associated with an inactivating alu insertion mutation of the calcium-sensing receptor gene. Am. J. Med. Genet. 71, 202-210.
51. Ray, K., Hauschild, B.C., Steinbach, P. J., Goldsmith, P. K., Hauache, O., and Spiegel, A. M. (1999) Identification of the cysteine residues in the amino-terminal extracellular domain of the human Ca2+ receptor critical for dimerization-implications for function of monomeric Ca2+ receptor. J. Biol. Chem. 274, 27642-27650.
52. Lienhardt, A., Bai, M., Lagarde, J. P., et al. (2001) Activating mutations of the calcium-sensing receptor: management of hypocalcemia. J. Clin. Endocrinol. Metab. 86, 5313-5323.
53. Hough, T. A., Bogani, D., Cheeseman, M. T., Favor, J., Nesbit, M. A., Thakker R. V., Lyon, M. F. 2004. Activating calcium-sensing receptor mutation in the mouse is associated with cataracts and ectopic calcification. Proc. Natl. Acad. Sci. U. S. A. 101(37):13566-71.
54. McLeod, D. R., Hanley, D. A., McArthur, R. G. 1989. Autosomal dominant hypoparathyroidism with intracranial calcification outside the basal ganglia. Am. J. Med. Genet. 32:32-5.
55. Zhang, P., Jobert, A. S., Couvineau, A., and Silve, C. (1998) Homozygous inactivating mutation in the parathyroid hormone parathyroid hormone-related peptide receptor causing Blomstrand chondrodysplasia. J. Clin. Endocrinol. Metab. 83, 3365-3368.
56. Cohen, D. P., Thaw, C. N., Varma, A., Gershengorn, M. C., and Nussenzveig, D. R. (1997) Human calcitonin receptors exhibit agonist-independent (constitutive) signaling activity. Endocrinology 138, 1400-1405.
57. Calvi, L. M., and Schipani, E. (2000) The PTH/PTHrP receptor in Jansen's metaphyseal chondrodysplasia. J. Endocrinol. Invest. 23, 545-554.
58. Tao, Y. X. (2006) Inactivating mutations of G protein-coupled receptors and diseases: structure-function insights and therapeutic implications. Pharmacol. Ther. 111, 949-973.
59. Hopyan, S., Gokgoz, N., Poon, R., et al. (2002) A mutant PTH/PTHrP type I receptor in enchondromatosis. Nat. Genet. 30, 306-310.
60. Duchatelet, S., Ostergaard, E., Cortes, D., Lemainque, A., and Julier, C. (2005) Recessive mutations in PTHRl cause contrasting skeletal dysplasias in Eiken and Blomstrand syndromes. Hum. Mol. Genet. 14, 1-5.
61. Kokkotou, E. G., Tritos, N. A., Mastaitis, J. W., Slieker, L., and Maratos-Flier, E. (2001) Melanin-concentrating hormone receptor is a target of leptin action in the mouse brain. Endocrinology. 142, 680-686.
62. Segal-Lieberman, G., Bradley, R. L., Kokkotou, E., et al. (2003) Melanin-concentrating hormone is a critical mediator of the leptin-deficient phenotype. Proc. Natl. Acad. Sci. U. S. A. 100, 10085-10090.
63. Segal-Lieberman, G., Trombly, D. J., Juthani, V., Wang, X. M., and Maratos-Flier, E. (2003) NPY ablation in C57BL/6 mice leads to mild obesity and to an impaired refeeding response to fasting. Am. J. Physiol. Endocrinol. Metab. 284, E1131-E1139.
64. Xu, Y. L., Jackson, V. R., and Civelli, O. (2004) Orphan G protein-coupled receptors and obesity. Eur. J. Pharmacol. 500, 243-253.
65. Vaisse, C., Clement, K., Guy-Grand, B., and Froguel, P. (1998) A frameshift mutation in human MC4R is associated with a dominant form of obesity. Nat. Genet. 20, 113-114.
66. Lubrano-Berthelier, C., Le Stunff, C., Bougneres, P., and Vaisse, C. (2004) Clinical case seminar-a homozygous null mutation delineates the role of the melanocortin-4 receptor in humans. J. Clin. Endocrinol. Metab. 89, 2028-2032.
67. Yeo, G. S. H., Farooqi, I. S., Aminian, S., Halsall, D. J., Stanhope, R. C., and O'Rahilly, S. (1998) A frameshift mutation in MC4R associated with dominantly inherited human obesity. Nat. Genet. 20, 111-112.
68. Yeo, G. S. H., Farooqi, I. S., Challis, B. G., Jackson, R. S., and O'Rahilly, S. (2000) The role of melanocortin signalling in the control of body weight: evidence from human and murine genetic models. Q. J. M. 93, 7-14.
69. Yeo, G. S. H., Lank, E. J., Farooqi, I. S., Keogh, J., Challis, B. G., and O'Rahilly, S. (2003) Mutations in the human melanocortin-4 receptor gene associated with severe familial obesity disrupts receptor function through multiple molecular mechanisms. Hum. Mol. Genet. 12, 561-574.
70. Lubrano-Berthelier, C., Cavazos, M., Lestunff, C., Bougneres, P., and Vaisse, C. (2003) Mutations in the transcriptionally essential region of the MC4R promoter are not a cause of severe obesity in humans. Diabetes. 52, A397.
71. O'Rahilly, S., Yeo, G. S. H., and Farooqi, I. S. (2004) Melanocortin receptors weigh in. Nat. Med. 10, 351-352.
72. Adan, R. A. H., and Kas, M. J. H. (2003) Inverse agonism gains weight. Trends Pharmacol. Sci. 24, 315-321.
73. Marsh, D. J., Hollopeter, G., Huszar, D., et al. (1999) Response of melanocortin-4 receptor-deficient mice to anorectic and orexigenic peptides. Nat. Genet. 21, 119-122.
74. Ste Marie, L., Miura, G. I., Marsh, D. J., Yagaloff, K., and Palmiter, R. D. (2000) A metabolic defect promotes obesity in mice lacking melanocortin-4 receptors. Proc. Natl. Acad. Sci. U. S. A. 97, 12339-12344.
75. Branson, R., Potoczna, N., Krai, J. G., Lentes, K., Hoehe, M. R., and Horber, F. F. (2003) Binge eating as a major phenotype of melanocortin 4 receptor gene mutations. N. Engl. J. Med. 348, 1096-1103.
76. List, J. F., and Habener, J. F. (2003) Defective melanocortin 4 receptors in hyperphagia and morbid obesity. N. Engl. J. Med. 348, 1160-1163.
77. Farooqi, I. S., Keogh, J. M., Yeo, G. S. H., Lank, E. J., Cheetham, T., and O'Rahilly, S. (2003) Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N. Engl. J. Med. 348, 1085-1095.
78. Vaisse, C., Clement, K., Durand, E., Hercberg, S., Guy-Grand, B., and Froguel, P. (2000) Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. J. Clin. Invest. 106, 253-262.
79. Fisher, M. J., Backer, R. T., Collado, I., et al. (2005) Privileged structure based ligands for melanocortin receptors - substituted benzylic piperazine derivatives. Bioorg. Med. Chem. Lett. 15, 4973-4978.
80. Kuklish, S. L., Backer, R. T., Briner, K., et al. (2006) Privileged structure based ligands for melanocortin receptors - 4,4-disubstituted piperidine derivatives. Bioorg. Med. Chem. Lett. 16, 3843-3846.
81. Nargund, R. P., Strack, A. M., and Fong, T. M. (2006) Melanocortin-4 receptor (MC4R) agonists for the treatment of obesity. J. Med. Chem. 49, 4035-4043.
82. Jiang, W., Tucci, F. C., Chen, C. W., et al. (2006) Arylpropionylpiperazines as antagonists of the human melanocortin-4 receptor. Bioorg. Med. Chem. Lett. 16, 4674-4678.
83. Gromoll, J., Simoni, M., Nordhoff, V., Behre, H. M., De Geyter, C., and Nieschlag, E. (1996) Functional and clinical consequences of mutations in the FSH receptor. Mol. Cell. Endocrinol. 125, 177-182.
84. Simoni, M., Nieschlag, E., and Gromoll, J. (2002) Isoforms and single nucleotide polymorphisms of the FSH receptor gene: implications for human reproduction. Hum. Reprod. Update. 8, 413-421.
85. Laven, J. S. E., Mulders, A. G. M. G., Suryandari, D. A., et al. (2003) Follicle-stimulating hormone receptor polymorphisms in women with normogonadotropic anovulatory infertility. Fertil. Steril. 80, 986-992.
86. Gromoll, J., Simoni, M., and Nieschlag, E. (1996) An activating mutation of the follicle-stimulating hormone receptor autonomously sustains spermatogenesis in a hypophysectomized man. J. Clin. Endocrinol. Metab. 81, 1367-1370.
87. Simoni, M., Gromoll, J., and Nieschlag, E. (1997) The follicle-stimulating hormone receptor: biochemistry, molecular biology, physiology, and pathophysiology. Endocr. Rev. 18, 739-773.
88. Simoni, M., Weinbauer, G. F., Gromoll, J., and Nieschlag, E. (1999) Role of FSH in male gonadal function. Ann. Endocrinol. (Paris). 60, 102-106.
89. De, L. A., Montanelli, L., Van, D. J., et al. (2006) Presence and absence of follicle-stimulating hormone receptor mutations provide some insights into spontaneous ovarian hyperstimulation syndrome physiopathology. J. Clin. Endocrinol. Metab. 91, 555-562.
90. Meehan, T. P., and Narayan, P. (2007) Constitutively active luteinizing hormone receptors: consequences of in vivo expression. Mol. Cell. Endocrinol. 260-262, 294-300.
91. Iiri, T., Herzmark, P., Nakamoto, J. M., Vandop, C., and Bourne, H. R. (1994) Rapid Gdp release from G(S-alpha) in patients with gain and loss of endocrine function. Nature. 371, 164-168.
92. Gromoll, J., Schulz, A., Borta, H., et al. (2002) Homozygous mutation within the conserved Ala-Phe-Asn-Glu-Thr motif of exon 7 of the LH receptor causes male pseudohermaphroditism. Eur. J. Endocrinol. 147, 597-608.
93. Schoneberg, T., Schulz, A., and Gudermann, T. (2002) The structural basis of G-protein-coupled receptor function and dysfunction in human diseases. Rev. Physiol. Biochem. Pharmacol. 144, 143-227.
94. Tsigos, C., Latronico, C., and Chrousos, G. P. (1997) Luteinizing hormone resistance syndromes. Ann. N. Y. Acad. Sci. 816, 263-273.
95. Latronico, A. C., Anasti, J., Arnhold, I. J., et al. (1995) A novel mutation of the luteinizing hormone receptor gene causing male gonadotropin-independent precocious puberty. J. Clin. Endocrinol. Metab. 80, 2490-2494.
96. Kosugi, S., Van Dop, C., Geffner, M. E., et al. (1995) Characterization of heterogeneous mutations causing constitutive activation of the luteinizing hormone receptor in familial male precocious puberty. Hum. Mol. Genet. 4, 183-188.
97. Seminara, S. B., Hayes, F. J., and Crowley, W. F. (1998) Gonadotropin-releasing hormone deficiency in the human (Idiopathic hypogonadotropic hypogonadism and Kallmann's syndrome): Pathophysiological and genetic considerations. Endocr. Rev. 19, 521-539.
98. Millar, R. P., Lu, Z. L., Pawson, A. J., Flanagan, C. A., Morgan, K., and Maudsley, S. R. (2004) Gonadotropin-releasing hormone receptors. Endocr. Rev. 25, 235-275.
99. Franco, B., Guioli, S., Pragliola, A., et al. (1991) A gene deleted in Kallmanns syndrome shares homology with neural cell-adhesion and axonal path-finding molecules. Nature. 353, 529-536.
100. Legouis, R., Hardelin, J. P., Levilliers, J., et al. (1991) The candidate gene for the X-linked Kallmann syndrome encodes a protein related to adhesion molecules. Cell. 67, 423-435.
101. Habiby, R. L., Boepple, P., Nachtigall, L., Sluss, P. M., Crowley, W. F., and Jameson, J. L. (1996) Adrenal hypoplasia congenita with hypogonadotropic hypogonadism-evidence that DAX-1 mutations lead to combined hypothalamic and pituitary defects in gonadotropin production. J. Clin. Invest. 98, 1055-1062.
102. Beranova, M., Oliveira, L. M. B., Bedecarrats, G. Y., et al. (2001) Prevalence, phenotypic spectrum, and modes of inheritance of gonadotropin-releasing hormone receptor mutations in idiopathic hypogonadotropic hypogonadism. J. Clin. Endocrinol. Metab. 86, 1580-1588.
103. deRoux, N., Young, J., Misrahi, M., et al. (1997) A family with hypogonadotropic hypogonadism and mutations in the gonadotropin-releasing hormone receptor. N. Engl. J. Med. 337, 1597-1602.
104. Layman, L. C., Cohen, D. P., Jin, M., et al. (1998) Mutations in gonadotropin-releasing hormone receptor gene cause hypogonadotropic hypogonadism. Nat. Genet. 18, 14-15.
105. Lin, L., Conway, G. S., Hill, N. R., Dattani, M. T., Hindmarsh, P. C., and Achermann, J. C. (2006) A homozygous R262Q mutation in the gonadotropin-releasing hormone receptor presenting as constitutional delay of growth and puberty with subsequent borderline oligospermia. J. Clin. Endocrinol. Metab. 91, 5117-5121.
106. Hoffmann, S. H., ter Laak, T., Kuhne, R., Reilander, H., and Beckers, T. (2000) Residues within transmembrane helices 2 and 5 of the human gonadotropin-releasing hormone receptor contribute to agonist and antagonist binding. Mol. Endocrinol. 14, 1099-1115.
107. Zhou, W., Rodic, V., Kitanovic, S., et al. (1995) A locus of the gonadotropin-releasing-hormone receptor that differentiates agonist and antagonist binding-sites. J. Biol. Chem. 270, 18853-18857.
108. Chauvin, S., Hibert, M., Berault, A., and Counis, R. (2001) Critical implication of transmembrane Phe310, possibly in conjunction with Trp279, in the rat gonadotropin-releasing hormone receptor activation. Biochem. Pharmacol. 62, 329-334.
109. Hammond, C., and Helenius, A. (1995) Quality-control in the secretory pathway. Curr. Opin. Cell. Biol. 1, 523-529.
110. Tsigos, C., Arai, K., Hung, W., and Chrousos, G. P. (1993) Hereditary isolated glucocorticoid deficiency is associated with abnormalities of the adrenocorticotropin receptor gene. J. Clin. Invest. 92, 2458-2461.
111. Tsiotra, P. C., Koukourava, A., Kaltezioti, V., et al. (2006) Compound heterozygosity of a frameshift mutation in the coding region and a single base substitution in the promoter of the ACTH receptor gene in a family with isolated glucocorticoid deficiency. J. Pediatr. Endocrinol. Metab. 19, 1157-1166.
112. Tsigos, C., Tsiotra, P., Garibaldi, L. R., Stavridis, J. C., Chrousos, G. P., and Raptis, S. A. (2000) Mutations of the ACTH receptor gene in a new family with isolated glucocorticoid deficiency. Mol. Genet. Metab. 71, 646-650.
113. Morin, D., Ala, Y., and Dumas, R. (1995) Hereditary nephrogenic diabetes insipidus. Arch. Pediatr. 2, 560-567.
114. Bichet, D. G., Turner, M., and Morin, D. (1998) Vasopressin receptor mutations causing nephrogenic diabetes insipidus. Proc. Assoc. Am. Physicians. 110, 387-394.
115. Szalai, C., Triga, D., and Czinner, A. (1998) C112R, W323S, N317K mutations in the vasopressin V2 receptor gene in patients with nephrogenic diabetes insipidus. Mutations in brief no. 165. Online. Hum. Mutat. 12, 137-138.
116. Ashida, A., Yamamoto, D., Nakakura, H., et al. (2007) A case of nephrogenic diabetes insipidus with a novel mis sense mutation in the AVPR2 gene. Pediatr. Nephrol. DOI:10.1007/S00467-006-0388-8.
117. Dong, Y., Sheng, H., Chen, X., Yin, J., and Su, Q. (2006) Deletion of the V2 vasopressin receptor gene in two Chinese patients with nephrogenic diabetes insipidus. B.M.C. Genet. 1, 53.
118. Oksche, A., Dickson, J., Schulein, R., et al. (1994) Two novel mutations in the vasopressin V2 receptor gene in patients with congenital nephrogenic diabetes insipidus. Biochem. Biophys. Res. Commun. 205, 552-527.
119. Pan, Y., Metzenberg, A., Das, S., Jing, B., and Gitschier, J. (1992) Mutations in the V2 vasopressin receptor gene are associated with X-linked nephrogenic diabetes insipidus. Nat. Genet. 2, 103-106.
120. Szalai, C., Molnar, E., Sallay, P., and Czinner, A. (1998) Molecular biological studies on patients with nephrogenic diabetes insipidus. Orv. Hetil. 139, 883-887.
121. Rosenthal, W., Seibold, A., Antaramian, A., et al. (1992) Molecular identification of the gene responsible for congenital nephrogenic diabetes insipidus. Nature. 359, 233-235.
122. Rosenthal, W., Seibold, A., Antaramian, A., et al. (1994) Mutations in the vasopressin V2 receptor gene in families with nephrogenic diabetes insipidus and functional expression of the Q-2 mutant. Cell. Mol. Biol. (Noisy-Le-Grand). 40, 429-436.
123. Rosenthal, W., Antaramian, A., Gilbert, S., and Birnbaumer, M. (1993) Nephrogenic diabetes insipidus. A V2 vasopressin receptor unable to stimulate adenylyl cyclase. J. Biol. Chem. 268, 13030-13033.
124. Seibold, A., January, B. G., Friedman, J., Hipkin, R. W., and Clark, R. B. (1998) Desensitization of beta2-adrenergic receptors with mutations of the proposed G protein-coupled receptor kinase phosphorylation sites. J. Biol. Chem. 273, 7637-7642.
125. Pierce, K. L., Premont, R. T., and Lefkowitz, R. J. (2002) Seven-transmembrane receptors. Nat. Rev. Mol. Cell. Biol. 3, 639-650.
126. Barak, L. S., Oakley, R. H., Laporte, S. A., and Caron, M. G. (2001) Constitutive arrestinmediated desensitization of a human vasopressin receptor mutant associated with nephrogenic diabetes insipidus. Proc. Natl. Acad. Sci. U. S. A. 98, 93-98.
127. Brooks A, O. B. H. R. (2005) Studying the genetics of Hirschsprung's disease: unraveling an oligogenic disorder. Clin. Genet. 67, 6-14.
128. Martucciello, G., Ceccherini, I., Lerone, M., and Jasonni, V. (2000) Pathogenesis of Hirschsprung's disease. J. Pediatr. Surg. 35, 1017-1025.
129. Kedzierski, R. M., Yanagisawa, M. (2001) Endothelin system: the double-edged sword in health and disease. Annu. Rev. Pharmacol. Toxicol. 41, 851-876.
130. Puffenberger, E. G., Hosoda, K., Washington, S. S., et al. (1994) A missense mutation of the endothelin-B receptor gene in multigenic Hirschsprung's disease. Cell. 79, 1257-1266.
131. Attie, T., Till, M., Pelet, A., et al. (1995) Mutation of the endothelin-receptor-B gene in Waardenburg-Hirschsprang-disease. Hum. Mol. Genet. 4, 2407-2409.
132. Hofstra, R. M. W., Osinga, J., TanSindhunata, G., et al. (1996) A homozygous mutation in the endothelin-3 gene associated with a combined Waardenburg type 2 and Hirschsprung phenotype (Shah-Waardenburg syndrome). Nat. Genet. 12, 445-447.
133. Hofstra, R. M. W., Valdenaire, O., Arch, E., et al. (1999) A loss-of-function mutation in the endothelin-converting enzyme 1 (ECE-1) associated with Hirschsprung disease, cardiac defects, and autonomic dysfunction. Am. J. Hum. Genet. 64, 304-308.
134. Fuchs, S., Amiel, J., Claudel, S., Lyonnet, S., Corvol, P., and Pinet, F. (2001) Functional characterization of three mutations of the endothelin B receptor gene in patients with Hirschsprung's disease: evidence for selective loss of G(i) coupling. Mol. Med. 1, 115-124.
135. Imamura, F., Arimoto, I., Fujiyoshi, Y., and Doi, T. (2000) W276 mutation in the endothelin receptor subtype B impairs G(q) but not G(i) or G(o) coupling. Biochemistry. 39, 686-692.
136. Hollopeter, G., Jantzen, H. M., Vincent, D., et al. (2001) Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature. 409, 202-207.
137. Conley, P. B., Jantzen, H. M., Vincent, D., et al. (2000) Molecular identification of the platelet ADP receptor targeted by antithrombotic drags. Blood. 96, 222A.
138. Laitinen, T., Polvi, A., Rydman, P., et al. (2004) Characterization of a common susceptibility locus for asthma-related traits. Science. 304, 300-304.
139. Kormann, M. S. D., Carr, D., Klopp, N., et al. (2005) G-protein-coupled receptor polymorphisms are associated with asthma in a large German population. Am. J. Respir. Crit. Care. Med. 171, 1358-1362.
140. Melen, E., Brace, S., Doekes, G., et al. (2005) Haplotypes of G protein-coupled receptor 154 are associated with childhood allergy and asthma. Am. J. Respir. Crit. Care. Med. 171, 1089-1095.
141. Kere, J., and Laitinen, T. (2004) Positionally cloned susceptibility genes in allergy and asthma. Curr. Opin. Immunol. 16, 689-694.